These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 21862107

  • 1. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [Abstract] [Full Text] [Related]

  • 2. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
    Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C.
    Ann Rheum Dis; 2012 Mar; 71(3):374-7. PubMed ID: 21972242
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J, Díaz-Torné C, Magallares B, Hernández MV, Reina D, Corominas H, Sanmartí R, de la Serna AR, Llobet JM, Nolla JM.
    PLoS One; 2015 Mar; 10(4):e0123392. PubMed ID: 25830224
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
    Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.
    Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP, RESET Investigators.
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [Abstract] [Full Text] [Related]

  • 7. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
    Bird P, Griffiths H, Tymms K, Nicholls D, Roberts L, Arnold M, Burnet S, de Jager J, Scott J, Zochling J, Littlejohn G.
    J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
    [Abstract] [Full Text] [Related]

  • 8. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F, Michaud K, Stephenson B, Doyle J.
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [Abstract] [Full Text] [Related]

  • 9. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Aug; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

  • 10. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [Abstract] [Full Text] [Related]

  • 11. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
    Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V.
    J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
    [Abstract] [Full Text] [Related]

  • 12. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P.
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [Abstract] [Full Text] [Related]

  • 13. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [Abstract] [Full Text] [Related]

  • 14. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
    Rigby WF, Mease PJ, Olech E, Ashby M, Tole S.
    J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
    [Abstract] [Full Text] [Related]

  • 17. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [Abstract] [Full Text] [Related]

  • 18. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 19. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
    Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y.
    Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
    [Abstract] [Full Text] [Related]

  • 20. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI.
    Scand J Rheumatol; 2009 Dec; 38(1):11-4. PubMed ID: 19191187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.